We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim
News

Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim

Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim
News

Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford BioTherapeutics has announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an ongoing discovery collaboration. The target was discovered using Oxford BioTherapeutics’ proprietary OGAP® system, which incorporates one of the world’s largest proprietary proteomic databases, integrating clinical, experimental and expression data.

This represents the first option exercised under the companies’ oncology target discovery and validation collaboration established in 2013. Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target. Oxford BioTherapeutics will receive development and regulatory milestone payments, and royalties on any future product sales.

“We are delighted to have reached this important milestone in the collaboration with Boehringer Ingelheim, which validates both our ongoing collaboration with a world-leading oncology company and our unique OGAP® target discovery system,” said Dr Christian Rohlff, CEO of Oxford BioTherapeutics.

Dr Rohlff continued, “Antibody therapeutics are a focus area for oncology R&D, and the selection of their targets is important for their success. With our world-leading targeting technology and in-house pipeline of novel antibody-drug conjugates, Oxford BioTherapeutics is rapidly establishing its position as a partner of choice for the development of new generation cancer therapeutics.”

Advertisement